Suppr超能文献

一种基于标准脂质谱计算小而密低密度脂蛋白胆固醇的新方程及其作为风险增强试验的应用。

A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test.

机构信息

Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.

Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

出版信息

Clin Chem. 2021 Jul 6;67(7):987-997. doi: 10.1093/clinchem/hvab048.

Abstract

BACKGROUND

Increased small dense low-density lipoprotein-cholesterol (sdLDL-C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD) but typically requires advanced lipid testing. We describe two new equations, first one for calculating large buoyant LDL-C (lbLDL-C), based only upon results from the standard lipid panel, and the second one for sdLDL-C.

METHODS

Equations for sdLDL-C and lbLDL-C were generated with least-squares regression analysis using the direct Denka sdLDL-C assay as reference (n = 20 171). sdLDL-C was assessed as a risk-enhancer test in the National Heart and Nutrition Examination Survey (NHANES), and for its association with ASCVD in the Multi-Ethnic Study of Atherosclerosis (MESA).

RESULTS

The newly derived equations depend on two terms, namely LDL-C as determined by the Sampson equation, and an interaction term between LDL-C and the natural log of triglycerides (TG). The lbLDL-C equation (lbLDLC=1.43 × LDLC-0.14 ×(ln⁡(TG)× LDLC)- 8.99) was more accurate (R2 = 0.933, slope = 0.94) than the sdLDL-C equation (sdLDLC=LDLC- lbLDLC; R2 = 0.745, slope = 0.73). Using the 80th percentile (46 mg/dL) as a cut-point, sdLDL-C identified in NHANES additional high-risk patients not identified by other risk-enhancer tests based on TG, LDL-C, apolipoprotein B, and nonHDL-C. By univariate survival-curve analysis, estimated sdLDL-C was superior to other risk-enhancer tests in predicting ASCVD events in MESA. After multivariate adjustment for other known ASCVD risk factors, estimated sdLDL-C had the strongest association with ASCVD compared to other lipid parameters, including measured sdLDL-C.

CONCLUSIONS

Estimated sdLDL-C could potentially be calculated on all patients tested with a standard lipid panel to improve ASCVD risk stratification.

摘要

背景

小而密的低密度脂蛋白胆固醇(sdLDL-C)升高是动脉粥样硬化性心血管疾病(ASCVD)的一个危险因素,但通常需要进行高级血脂检测。我们描述了两种新的方程,第一个是仅基于标准血脂谱计算大浮力 LDL-C(lbLDL-C)的方程,第二个是计算 sdLDL-C 的方程。

方法

使用直接 Denka sdLDL-C 检测作为参考(n=20171),通过最小二乘回归分析生成 sdLDL-C 和 lbLDL-C 的方程。在国家心脏和营养检查调查(NHANES)中,sdLDL-C 被评估为风险增强测试,在多民族动脉粥样硬化研究(MESA)中,sdLDL-C 与 ASCVD 的相关性进行了评估。

结果

新推导出的方程取决于两个项,即 Sampson 方程确定的 LDL-C,以及 LDL-C 和甘油三酯(TG)的自然对数之间的交互项。lbLDL-C 方程(lbLDLC=1.43×LDLC-0.14×(ln⁡(TG)×LDLC)-8.99)更准确(R2=0.933,斜率=0.94)比 sdLDL-C 方程(sdLDLC=LDLC-lbLDLC;R2=0.745,斜率=0.73)。使用第 80 百分位数(46mg/dL)作为切点,sdLDL-C 在 NHANES 中识别出了其他风险增强测试(基于 TG、LDL-C、载脂蛋白 B 和非 HDL-C)未识别的高危患者。通过单变量生存曲线分析,在 MESA 中,估计的 sdLDL-C 在预测 ASCVD 事件方面优于其他风险增强测试。在对其他已知 ASCVD 风险因素进行多变量调整后,与其他脂质参数(包括测量的 sdLDL-C)相比,估计的 sdLDL-C 与 ASCVD 的相关性最强。

结论

估计的 sdLDL-C 可以潜在地计算所有用标准血脂谱检测的患者,以改善 ASCVD 风险分层。

相似文献

8
Validation of Estimated Small Dense Low-Density Lipoprotein Cholesterol Concentration in a Japanese General Population.
J Atheroscler Thromb. 2024 Jun 1;31(6):931-952. doi: 10.5551/jat.64578. Epub 2023 Dec 29.
9
An increase in calculated small dense low-density lipoprotein cholesterol predicts new onset of hypertension in a Japanese cohort.
Hypertens Res. 2023 Dec;46(12):2635-2645. doi: 10.1038/s41440-023-01392-x. Epub 2023 Aug 2.

引用本文的文献

1
Estimated Small, Dense LDL Cholesterol and Atherosclerotic Cardiovascular Risk in the UK Biobank.
Arterioscler Thromb Vasc Biol. 2025 Aug 14. doi: 10.1161/ATVBAHA.125.323157.
2
Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus.
Front Endocrinol (Lausanne). 2025 Jul 17;16:1496671. doi: 10.3389/fendo.2025.1496671. eCollection 2025.
3
Discordance of Small Dense LDL Cholesterol Beyond LDL Cholesterol or Non-HDL Cholesterol and Carotid Plaque.
JACC Asia. 2025 Aug;5(8):1012-1028. doi: 10.1016/j.jacasi.2025.04.015. Epub 2025 Jul 8.
10
Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study.
BMC Gastroenterol. 2025 Mar 13;25(1):168. doi: 10.1186/s12876-025-03759-5.

本文引用的文献

3
LDL Cholesterol: What Is the Best Way to Measure It?
Clin Chem. 2019 Sep;65(9):1067-1069. doi: 10.1373/clinchem.2019.307678. Epub 2019 Jul 15.
4
Residual cardiovascular risk among people with diabetes.
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:28-38. doi: 10.1111/dom.13646.
5
Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation.
Nutr Metab (Lond). 2019 Jan 21;16:7. doi: 10.1186/s12986-019-0334-y. eCollection 2019.
7
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):e1-e9. doi: 10.1161/ATVBAHA.118.311999.
8
ApoB in clinical care: Pro and Con.
Atherosclerosis. 2019 Mar;282:169-175. doi: 10.1016/j.atherosclerosis.2018.11.001. Epub 2018 Nov 10.
9
CETP Inhibitors - A New Inning?
N Engl J Med. 2017 Sep 28;377(13):1284-1285. doi: 10.1056/NEJMe1711407.
10
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验